Dacetuzumab

Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody^[1] being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma^[2] and hematological malignancies.^[3]

Dacetuzumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD40
Clinical data
Other names	SGN-40
ATC code	none
Identifiers
CAS Number	880486-59-9 N
ChemSpider	none
UNII	UT59FF4T5X
Chemical and physical data
Formula	C6452H9964N1732O1998S42
Molar mass	145111.33 g·mol−1
NY (what is this?)  (verify)

This drug was developed by Seattle Genetics, Inc.